We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

64 hedge funds and large institutions have $187M invested in Strongbridge Biopharma plc. in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

4% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 25

2% less funds holding

Funds holding: 65 → 64 (-1)

31% less capital invested

Capital invested by funds: $273M → $187M (-$85.6M)

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
64
Holders Change
-1
Holders Change %
-1.54%
% of All Funds
1.46%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
24
Increased
19
Reduced
12
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LSC
Lyon Street Capital
California
+$10.1M
2
SFM
Sphera Funds Management
Israel
+$4.93M
3
Millennium Management
Millennium Management
New York
+$3.84M
4
Goldman Sachs
Goldman Sachs
New York
+$2.62M
5
PWAM
Park West Asset Management
California
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$9.32M
2
AC
Armistice Capital
New York
-$8.88M
3
BC
Broadfin Capital
New York
-$3.32M
4
State Street
State Street
Massachusetts
-$2.61M
5
Northern Trust
Northern Trust
Illinois
-$2.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
$32.4M +$161K +21,995 +0.4%
LSC
2
Lyon Street Capital
California
$27.4M +$10.1M +1,383,484 +43%
NMC
3
NEA Management Company
Maryland
$24.8M – – –
BC
4
Broadfin Capital
New York
$14M -$3.32M -453,103 -16%
AC
5
Armistice Capital
New York
$12.9M -$8.88M -1,214,000 -36%
VC
6
Vivo Capital
California
$11.5M – – –
OM
7
Opaleye Management
Massachusetts
$11M +$1.76M +240,000 +15%
PWAM
8
Park West Asset Management
California
$6.49M +$2.19M +300,000 +38%
HCS
9
Harvest Capital Strategies
California
$5.8M +$1.04M +142,243 +17%
SFM
10
Sphera Funds Management
Israel
$4.04M +$4.93M +673,996 New
Millennium Management
11
Millennium Management
New York
$3.98M +$3.84M +524,539 +380%
GPCM
12
Granite Point Capital Management
Massachusetts
$3.41M – – –
BlackRock
13
BlackRock
New York
$3.13M -$9.32M -1,274,135 -71%
Goldman Sachs
14
Goldman Sachs
New York
$2.33M +$2.62M +357,643 +1,163%
PM
15
Precept Management
Texas
$2.07M -$915K -125,000 -27%
PA
16
Perceptive Advisors
New York
$1.65M – – –
Hudson Bay Capital Management
17
Hudson Bay Capital Management
Connecticut
$1.65M +$219K +30,000 +12%
EIM
18
Essex Investment Management
Massachusetts
$1.6M +$1.82K +249 +0.1%
6CM
19
683 Capital Management
New York
$1.5M – – –
TAF
20
Tredje AP-fonden
Sweden
$1.35M -$1.46M -200,000 -47%
IECM
21
Intrinsic Edge Capital Management
Illinois
$1.2M +$1.46M +200,000 New
Morgan Stanley
22
Morgan Stanley
New York
$1.16M +$611K +83,568 +76%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.03M +$386K +52,800 +44%
ECM
24
Element Capital Management
New York
$1.03M +$1.26M +172,121 New
BCM
25
BlueCrest Capital Management
Jersey
$854K +$1.04M +142,260 New
1
2 3 4

SBBP Hedge Fund Activity: Q2 2018 in Review

64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2018, worth a combined $187M — down 31% from $273M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of SBBP and 24 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 19 added.

The largest buyer was Lyon Street Capital, adding an estimated $10.1M. The largest seller was BlackRock, cutting an estimated $9.32M.

  • 64 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2018, down from 65 in Q1 2018.
  • Funds reported $187M of Strongbridge Biopharma plc. stock for Q2 2018, down 31% quarter-over-quarter.
  • 24 funds opened new Strongbridge Biopharma plc. positions in Q2 2018 and 25 closed out, a net change of -1 holder.
  • The largest Strongbridge Biopharma plc. buyer in Q2 2018 was Lyon Street Capital, an estimated $10.1M added.
  • The largest Strongbridge Biopharma plc. seller in Q2 2018 was BlackRock, an estimated $9.32M sold.

Based on aggregated 13F filings for Q2 2018.